Added to YB: 2025-11-19
Pitch date: 2025-11-17
QURE [neutral]
uniQure N.V.
-26.42%
current return
Author Info
No bio for this author
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.9B
Pitch Price
$29.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.44
P/E
-6.88
EV/Sales
107.85
Sector
Biotechnology
Category
growth
UniQure’s AMT-130: The First Therapy to Slow Huntington’s Disease Progression?
QURE (update): AMT-130 gene therapy directly targets striatum (HD disease epicenter) vs failed Tominersen which hit whole brain but missed striatum. 8% NfL reduction over 3yrs (brain degeneration marker) vs expected 30%+ increase. Propensity-matched natural history shows 75% slower decline. mHTT reduction irrelevant as only striatal matters, not measurable globally.
Read full article (6 min)